These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Editorial comment on: Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Korfage IJ Eur Urol; 2009 Feb; 55(2):432. PubMed ID: 18783875 [No Abstract] [Full Text] [Related]
28. Pathological features after radical prostatectomy in potential candidates for active monitoring. Griffin CR; Yu X; Loeb S; Desireddi VN; Han M; Graif T; Catalona WJ J Urol; 2007 Sep; 178(3 Pt 1):860-3; discussion 863. PubMed ID: 17631347 [TBL] [Abstract][Full Text] [Related]
29. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience. Xylinas E; Drouin SJ; Comperat E; Vaessen C; Renard-Penna R; Misrai V; Bitker MO; Chartier-Kastler E; Richard F; Cussenot O; Roupret M BJU Int; 2009 May; 103(9):1173-8; discussion 1178. PubMed ID: 19040530 [TBL] [Abstract][Full Text] [Related]
30. Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy. Cheng L; Davidson DD; Lin H; Koch MO Cancer; 2007 Nov; 110(9):1967-72. PubMed ID: 17823907 [TBL] [Abstract][Full Text] [Related]
32. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677 [TBL] [Abstract][Full Text] [Related]
33. Re: Prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. Schulz RJ; Kagan AR J Natl Cancer Inst; 2009 Jan; 101(2):124. PubMed ID: 19141784 [No Abstract] [Full Text] [Related]
34. Predictive significance of surgical margin status after prostatectomy for prostate cancer during PSA era. Mann MJ; DeCastro GJ; Desai M; Benson MC; McKiernan JM Urology; 2008 Dec; 72(6):1203-7. PubMed ID: 18674807 [TBL] [Abstract][Full Text] [Related]
35. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening. Postma R; Schröder FH; van Leenders GJ; Hoedemaeker RF; Vis AN; Roobol MJ; van der Kwast TH Eur Urol; 2007 Jul; 52(1):89-97. PubMed ID: 17257742 [TBL] [Abstract][Full Text] [Related]
36. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan. Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752 [TBL] [Abstract][Full Text] [Related]
37. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175 [TBL] [Abstract][Full Text] [Related]
38. Implementation of a map in radical prostatectomy specimen allows visual estimation of tumor volume. Bettendorf O; Oberpenning F; Köpke T; Heinecke A; Hertle L; Boecker W; Semjonow A Eur J Surg Oncol; 2007 Apr; 33(3):352-7. PubMed ID: 17175129 [TBL] [Abstract][Full Text] [Related]
39. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers. Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Frank I; Blute ML BJU Int; 2008 Feb; 101(3):299-304. PubMed ID: 17922854 [TBL] [Abstract][Full Text] [Related]
40. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy. D'Amico A BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]